Adjuvant cemiplimab therapy reduced the risk for disease recurrence or death by 68% compared with placebo in patients with high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy.

Please provide your email address to receive an email when new articles are posted on . The FDA has approved cemiplimab-rwlc for adjuvant treatment of adults with cutaneous squamous cell carcinoma at ...

May 18 (Reuters) - Shares of Regeneron fell 11.8% premarket on Monday after the company's experimental treatment missed the ...

Regeneron’s phase 3 trial of the LAG-3 inhibitor fianlimab plus cemiplimab failed to meet its primary endpoint of progression-free survival in first-line advanced melanoma.

The FDA has approved cemiplimab (Libtayo, Regeneron) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at a high risk for recurrence after surgery and radiation. The ...

REGN's melanoma combo misses the primary endpoint in a phase III study despite longer median PFS versus Keytruda monotherapy.

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) PD-1 inhibitor Libtayo (cemiplimab-rwlc) as an adjuvant treatment for adult patients ...

Cemiplimab is used to treat certain types of cancer (such as skin, lung). It works by changing the action of your own immune system, directing it to attack cancer cells. Cemiplimab belongs to a class ...

The stock fell sharply after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.